SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AMLMay S.K. Sutherland, Julie A. McEarchern, Changpu Yu et al.|Blood|2013Cited by 385
Development of orally active inhibitors of protein and cellular fucosylationNicole M. Okeley, Peter D. Senter, Stephen C. Alley et al.|Proceedings of the National Academy of Sciences|2013Cited by 189